TY - JOUR
T1 - Evolution of long-term outcome of liver resection for colorectal metastases
T2 - Analysis of actual 5-year survival rates over two decades
AU - Viganò, Luca
AU - Russolillo, Nadia
AU - Ferrero, Alessandro
AU - Langella, Serena
AU - Sperti, Elisa
AU - Capussotti, Lorenzo
PY - 2012/6
Y1 - 2012/6
N2 - Background. Liver resection (LR) is the only potentially curative treatment of colorectal liver metastases (CRLM). Its outcome over the past 2 decades was studied using actual 5-year survival rates. Methods. Data of 393 consecutive patients who underwent LR for CRLM at Mauriziano Umberto I (Turin) until June 2005 were analyzed. Excluding R2 resections (n = 4) or incomplete 5-year follow-up (n = 13), 376 patients were divided according to LR date into groups A (before 1995: 90 patients), B (1995-2000: 94 patients), C (2001-2005: 192). Results. Group C presented increased multiple and bilobar metastases compared with combined groupAandB(C vsAB: 54.7% vs 40.2%, P = 0.005; 28.1% vs 19.0%, P = 0.038, respectively), decreased metastases diameter (C vs AB: 32 vs 40 mm, P = 0.0001). The 5-year overall survival, calculated excluding 4 operative mortalities (group AB), increased over the years (A, 20.5%; B, 32.6%; C, 46.4%; P
AB - Background. Liver resection (LR) is the only potentially curative treatment of colorectal liver metastases (CRLM). Its outcome over the past 2 decades was studied using actual 5-year survival rates. Methods. Data of 393 consecutive patients who underwent LR for CRLM at Mauriziano Umberto I (Turin) until June 2005 were analyzed. Excluding R2 resections (n = 4) or incomplete 5-year follow-up (n = 13), 376 patients were divided according to LR date into groups A (before 1995: 90 patients), B (1995-2000: 94 patients), C (2001-2005: 192). Results. Group C presented increased multiple and bilobar metastases compared with combined groupAandB(C vsAB: 54.7% vs 40.2%, P = 0.005; 28.1% vs 19.0%, P = 0.038, respectively), decreased metastases diameter (C vs AB: 32 vs 40 mm, P = 0.0001). The 5-year overall survival, calculated excluding 4 operative mortalities (group AB), increased over the years (A, 20.5%; B, 32.6%; C, 46.4%; P
UR - http://www.scopus.com/inward/record.url?scp=84865136435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865136435&partnerID=8YFLogxK
U2 - 10.1245/s10434-011-2186-1
DO - 10.1245/s10434-011-2186-1
M3 - Article
C2 - 22219066
AN - SCOPUS:84865136435
VL - 19
SP - 2035
EP - 2044
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
IS - 6
ER -